Nano‑X Imaging Ltd. (NASDAQ: NNOX) announced that its U.S. subsidiary, Nanox Impact Inc., has signed a distribution agreement with NuvioDx LLC, a provider of imaging solutions focused on expanding access to diagnostic imaging. The partnership will allow NuvioDx to deploy Nano‑X’s Nanox.ARC multi‑source digital tomosynthesis systems across clinical sites in multiple U.S. states.
The Nanox.ARC system is FDA‑cleared and delivers 3‑D imaging at a lower cost and with a reduced radiation dose compared with traditional CT scanners. By leveraging NuvioDx’s regional market access and operational capabilities, Nano‑X aims to increase system activation and utilization in hospitals and point‑of‑care clinics, accelerating the commercial rollout of its core imaging platform.
This agreement is part of Nano‑X’s broader strategy to broaden its channel partner network. The company has recently announced similar distribution deals with Radiology Oncology Systems and Howard Technology Solutions, underscoring a concerted effort to expand its U.S. footprint and drive adoption of the Nanox.ARC system across diverse clinical settings.
Nano‑X’s financial performance has been challenging. In Q4 2025 the company reported a net loss of $33.4 million on revenue of $3.7 million, and its full‑year 2025 results showed a net loss of $75 million. Margins have remained negative, and the company has expressed concerns about converting distribution agreements into meaningful revenue while it continues to seek additional financing.
Erez Meltzer, CEO of Nano‑X, said, "This collaboration represents an important step in strengthening our commercialization strategy and expanding our channel partner network." Richard Gastineau, Managing Director of NuvioDx, added, "NuvioDX is excited about the opportunity to partner with Nano X Imaging Ltd. and bring cutting‑edge, innovative healthcare technology solutions to the marketplace. We believe Nano X Imaging Ltd.'s technology is strongly positioned to help providers enhance patient care, improve outcomes, and ultimately contribute to a better quality of life for the communities they serve."
Analysts have issued mixed ratings for Nano‑X, with some designating a “Moderate Buy” and others a “Strong Buy.” While concerns remain about the company’s ability to translate distribution agreements into substantial revenue, the partnership with NuvioDx is viewed as a potential catalyst for increasing activation of the Nanox.ARC system and improving the company’s revenue trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.